699 results on '"Feagan, B"'
Search Results
152. DOP79 Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
153. OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
154. Review article: Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy
155. Budesonide controlled ileal release prolonged remission in Crohn's disease: A pooled analysis 11.04
156. A Randomized Study Comparing Patient-Directed Hypertension Management with Usual Office-Based Care: PIII-58
157. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
158. Oral Budesonide is Effective In Active Crohnʼs Disease
159. Editorial: aminosalicylates in Crohn's disease-prevalence, risks, costs and time to reassess? Authors’ reply
160. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease
161. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease
162. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
163. Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE-HSS)-an important first step. Authors’ reply
164. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis
165. Reliability of histologic assessment in patients with eosinophilic oesophagitis
166. A114 SYSTEMATIC REVIEW AND META-ANALYSIS: ENDOSCOPIC AND HISTOLOGIC PLACEBO RATES IN INDUCTION AND MAINTENANCE TRIALS OF ULCERATIVE COLITIS
167. A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN’S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY
168. A333 THE ROLE OF IMAGING IN DETERMINING PROGNOSIS FOR PRIMARY SCLEROSING CHOLANGITIS: A SYSTEMATIC REVIEW
169. A92 ANTIBIOTICS FOR INDUCTION AND MAINTENANCE OF REMISSION IN CROHN’S DISEASE
170. A111 INFLIXIMAB FOR INDUCTION OF REMISSION IN CROHN’S DISEASE
171. A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE
172. A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS
173. P544 Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study
174. P186 Outcomes of maintenance ustekinumab therapy for Crohn’s disease based on inflammatory burden: A post-hoc analysis of the UNITI trials
175. P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies
176. P676 Correlation of lipid levels with reduction in inflammation in patients with ulcerative colitis: Data from the tofacitinib OCTAVE clinical trials
177. P533 Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study
178. Ustekinumab as induction and maintenance therapy for Crohn's disease
179. Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
180. LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARS
181. The development of a magnetic resonance imaging index for fistulising Crohn's disease
182. AODWE-006 Efficacy of ustekinumab for induction and maintenance of histological healing in patient’s with crohn’s disease
183. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
184. Editorial: the impact of the placebo effect in Crohn's disease - author's reply
185. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis
186. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease
187. Placebo response and remission rates in Ulcerative Colitis clinical trials: Systematic review and meta-analysis
188. Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel
189. Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
190. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
191. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1
192. PTH-052 Efficacy of Vedolizumab with and Without Continued Immunosuppressant Use in Gemini 1 and Gemini 2: Abstract PTH-052 Table 1
193. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2: Abstract OC-007 Table 1
194. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis
195. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE):Determining Therapeutic Goals for Treat-to-Target
196. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
197. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials
198. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
199. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease
200. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.